CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 27, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming virtual investor conferences:

- **Jefferies Global Healthcare Conference** on Wednesday, June 3, 2020 at 10:30 a.m. ET.
- **Goldman Sachs 41st Annual Global Healthcare Conference** on Thursday, June 11, 2020 at 2:10 p.m. ET.

A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at [investors.modernatx.com](http://investors.modernatx.com). A replay of each webcast will be archived on Moderna’s website for 30 days following the presentation.

**About Moderna**

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit [www.modernatx.com](http://www.modernatx.com).


**Investors:**

Lavina Talukdar  
Head of Investor Relations  
617-209-5834  
Lavina.Talukdar@modernatx.com

Source: Moderna, Inc.